News

iOmx Therapeutics announces discovery of novel, druggable immune-checkpoint targets

Details

iOmx Therapeutics announced today the presentation of two posters at the Fifth International Cancer lmmunotherapy Conference (CICON 2019) which showcases the company’s proprietary, high-throughput genetic screening platform, iOTarg™. iOTarg is designed to broadly screen tumor cells for hijacked immune checkpoints, which enable targeting of the tumor´s immune resistance mechanisms. 

STipe Therapeutics launches with EUR 20 million Series A financing

Details

STipe Therapeutics, a company founded to exploit a novel approach to the stimulator of interferon genes (STING) Pathway, a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders, launched today with an EUR 20 million Series A financing. The round was co-led by Novo Holdings and Arix Bioscience plc who were joined by Wellington Partners Life Science V Fund and Sunstone Life Science Ventures A/S. 

Adrenomed completes full enrollment with 300 patients in AdrenOSS-2 trial with Adrecizumab in septic shock

Details

Adrenomed announced today the successful completion of patient enrollment in the proof-of-concept Phase II trial, AdrenOSS-2, evaluating Adrecizumab in patients with early septic shock. Adrecizumab is a first-in-class antibody targeting the vasoprotective peptide Adrenomedullin to restore and maintain vascular integrity in life-threatening conditions associated with vascular leakage, congestion and shock. 

  1. FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019
  2. Themis raises EUR 40 Million in Series D financing round backed by US/EU consortium
  3. Adrenomed Supervisory Board appoints Jens Schneider-Mergener as CEO & Jens Zimmermann (CMO) joins the Executive Board
  4. Immatics and Celgene enter strategic collaboration to develop novel adoptive cell therapies
© Wellington Partners, 2019.